Clinical benefit and price hit the sweet spot, according to draft report
Rivaroxaban (Xarelto) added to aspirin and icosapent ethyl (Vascepa) added to standard prevention therapies are of at least modest net clinical benefit and cost-effective, according to a preliminary report from the Institute for Clinical and Economic Review (ICER).